|
Variables
|
MACE
|
Total (n = 276)
|
p value
|
|---|
|
No (n = 212)
|
Yes (n = 64)
|
|---|
|
Treatments
| | | |
0.071†
|
|
Conservative
|
43 (20.3)
|
20 (31.3)
|
63 (22.8)
| |
|
PCI
|
83 (39.2)
|
27 (42.2)
|
110 (39.9)
| |
|
CABG
|
86 (40.6)
|
17 (26.6)
|
103 (37.3)
| |
|
Coronary angiogram
|
|
Left main disease
|
27 (12.7)
|
5 (7.8)
|
32 (11.6)
|
0.281†
|
|
Single-vessel disease
|
82 (38.7)
|
23 (35.9)
|
105 (38.0)
|
0.692†
|
|
Two-vessel disease
|
39 (18.4)
|
17 (26.6)
|
56 (20.3)
|
0.155†
|
|
Three-vessel disease
|
79 (37.3)
|
20 (31.3)
|
99 (35.9)
|
0.177†
|
|
Discharge therapy
| | | | |
|
Beta blockers
|
158 (74.5)
|
42 (65.6)
|
200 (72.5)
|
0.162†
|
|
ACE-I/ARB
|
132 (62.)
|
44 (68.8)
|
176 (63.8)
|
0.344†
|
|
ASA
|
199 (93.9)
|
60 (93.8)
|
259 (93.8)
|
0.973†
|
|
P2Y12 inhibitors
|
182 (85.8)
|
50 (78.1)
|
232 (84.1)
|
0.139†
|
|
Statins
|
196 (92.5)
|
56 (87.5)
|
252 (91.3)
|
0.218†
|
|
Risk scores
| | | | |
|
GRACE 2.0
|
99.0 (80.3–116.0)
|
107.5 (88.5–127.3)
|
100.0 (82.0–120.0)
|
0.072*
|
|
ACEF
|
1.1 (0.9–1.3)
|
1.3 (0.9–1.4)
|
1.2 (0.9–1.3)
|
0.002‡
|
|
SYNTAX
|
14.0 (8.0–23.4)
|
13.3 (7.0–26.0)
|
14.0 (8.0–24.0)
|
0.869‡
|
|
Clinical SYNTAX
|
14.8 (8.6–26.9)
|
15.1 (8.4–31.0)
|
14.9 (8.6–27.7)
|
0.462‡
|
|
SYNTAX II PCI
|
25.5 (20.4–33.7)
|
29.8 (24.1–38.5)
|
26.8 (20.8–34.8)
|
0.001*
|
|
SYNTAX II CABG
|
24.9 (17.2–32.0)
|
27.0 (18.7–36.4)
|
25.5 (18.1–33.6)
|
0.038*
|
- Data are expressed as number (percent) or median (interquartile range)
- ACE-I—angiotensin converting enzyme inhibitors; ACEF—Age, Creatinine and Ejection Fraction risk score; ARB—angiotensin receptor blockers; ASA—acetylsalicylic acid; CABG—coronary artery bypass grafting; GRACE—Global Registry of Acute coronary events risk score; MACE—major adverse cardiovascular events; PCI—percutaneous coronary intervention; SYNTAX—The Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery risk score
- *Student’s T test; †Chi-square test; ‡Mann–Whitney U test
